T-cell response dynamics in animal models of multiple sclerosis: Implications for immunotherapies

Expert Review of Clinical Immunology

Volumn 3, Issue 1, 2007, Pages 57-72

  Schreiner, Bettina ^a   Bailey, Samantha L ^a   Miller, Stephen D ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEMTUZUMAB; ANTIINFECTIVE AGENT; BETA INTERFERON; CD40 LIGAND MONOCLONAL ANTIBODY; DACLIZUMAB; ESTRADIOL; FINGOLIMOD; GLATIRAMER; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 12P70 ANTIBODY; INTERLEUKIN 23P19 ANTIBODY; INTERLEUKIN 23P40 ANTIBODY; MINOCYCLINE; MITOXANTRONE; MONOCLONAL ANTIBODY CD28; MYELIN; NATALIZUMAB; PIOGLITAZONE; PLACEBO; PROGESTERONE; RAPAMYCIN; RILUZOLE; RITUXIMAB; ROSIGLITAZONE; TERIFLUNOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE LEUKEMIA; ALLERGIC ENCEPHALOMYELITIS; ANIMAL MODEL; ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CARDIOTOXICITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE EXACERBATION; DISEASE MODEL; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; LYMPHOCYTE TRANSFUSION; MULTIPLE SCLEROSIS; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

EID: 33947208933     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.1.57     Document Type: Review

References (187)

1. Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112, 1419-1428 (1989).
2. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33, 1444-1452 (1983).
3. Cutter GR, Baier ML, Rudick RA et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122, 871-882 (1999).
4. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 127, 1463-1478 (2004).
5. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50, 121-127 (2001).
6. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron 24, 511-514 (1999).
7. Pelfrey CM, Rudick RA, Cotleur AC, Lee JC, Tary-Lehmann M, Lehmann PV. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J. Immunol. 165, 1641-1651 (2000).
8. Correale J, Gilmore W, McMillan M et al. Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis. J. Immunol. 154, 2959-2968 (1995).
9. Voskuhl RR, Martin R, Bergman C, Dalal M, Ruddle NH, McFarland HF. T helper 1 (Th1) functional phenotype of human myelin-basic protein-specific T lymphocytes. Autoimmunity 15, 137-143 (1993).
10. Hemmer B, Vergelli M, Calabresi P, Huang T, McFarland HF, Martin R. Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83-99). J. Neurosci. Res. 45, 852-862 (1996).
11. Panitch HS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with γ interferon: exacerbations associated with activation of the immune system. Neurology 37, 1097-1102 (1987).
12. Lublin FD, Knobler RL, Kalman B et al. Monoclonal anti-γ interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity 16, 267-274 (1993).
13. Duong TT, St, Gilbert JJ, Finkelman FD, Strejan GH. Effect of anti-interferon-γ and anti-interleukin-2 monoclonal antibody treatment on the development of actively and passively induced experimental allergic encephalomyelitis in the SJL/J mouse. J. Neuroimmunol. 36, 105-115 (1992).
14. Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
15. Park H, Li Z, Yang XO et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133-1141 (2005).
16. Chen Y, Langrish CL, McKenzie B et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 116, 1317-1326 (2006).
17. Matusevicius D, Kivisakk P, He B et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult. Scler. 5, 101-104 (1999).
18. Ishizu T, Osoegawa M, Mei FJ et al. Intrathecal activation of the IL-17/ IL-8 axis in opticospinal multiple sclerosis. Brain 128, 988-1002 (2005).
19. Lock C, Hermans G, Pedotti R et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8, 500-508 (2002).
20. Hafler DA, Slavik JM, Anderson DE, O'Connor KC, De Jager P, Baecher-Allan C. Multiple sclerosis. Immunol. Rev. 204, 208-231 (2005).
21. Lassmann H, Ransohoff RM. The CD4-Th1 model for multiple sclerosis: a critical re-appraisal. Trends Immunol. 25, 132-137 (2004).
22. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707-717 (2000).
23. O'Connor KC, Bar-Or A, Hafler DA. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J. Clin. Immunol. 21, 81-92 (2001).
24. Cross AH, Trotter JL, Lyons J. B cells and antibodies in CNS demyelinating disease. J. Neuroimmunol. 112, 1-14 (2001).
25. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23, 683-747 (2005).
26. Krogsgaard M, Wucherpfennig KW, Cannella B et al. Visualization of myelin basic protein (MBP) T cell epitopes in multiple sclerosis lesions using a monoclonal antibody specific for the human histocompatibility leukocyte antigen (HLA)-DR2-MBP 85-99 complex. J. Exp. Med. 191, 1395-1412 (2000).
27. Madsen LS, Andersson EC, Jansson L et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat. Genet. 23, 343-347 (1999).
28. Hoftberger R, Aboul-Enein F, Brueck W et al. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 14, 43-50 (2004).
29. Traugott U, Raine CS. Multiple sclerosis. Evidence for antigen presentation in situ by endothelial cells and astrocytes. J. Neurol. Sci. 69, 365-370 (1985).
30. Ransohoff RM, Estes ML. Astrocyte expression of major histocompatibility complex gene products in multiple sclerosis brain tissue obtained by stereotactic biopsy. Arch. Neurol. 48, 1244-1246 (1991).
31. Grenier Y, Ruijs TC, Robitaille Y, Olivier A, Antel JP. Immunohistochemical studies of adult human glial cells. J. Neuroimmunol. 21, 103-115 (1989).
32. Prineas JW, Wright RG. Macrophages, lymphocytes, and plasma cells in the perivascular compartment in chronic multiple sclerosis. Lab. Invest. 38, 409-421 (1978).
33. Raine CS, Scheinberg L, Waltz JM. Multiple sclerosis. Oligodendrocyte survival and proliferation in an active established lesion. Lab. Invest. 45, 534-546 (1981).
34. Barnett MH, Henderson AP, Prineas JW. The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Mult. Scler. 12, 121-132 (2006).
35. Boven LA, Van Meurs M, Van Zwam M et al. Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain 129, 517-526 (2006).
36. Greter M, Heppner FL, Lemos MP et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 11, 328-334 (2005).
37. Serafini B, Rosicarelli B, Magliozzi R et al. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J. Neuropathol. Exp. Neurol. 65, 124-141 (2006).
38. Pashenkov M, Huang YM, Kostulas V, Haglund M, Soderstrom M, Link H. Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain 124, 480-492 (2001).
39. Hohlfeld R, Wekerle H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. USA 101, 14599-14606 (2004).
40. Ercolini AM, Miller SD. Mechanisms of immunopathology in murine models of central nervous system demyelinating disease. J. Immunol. 176, 3293-3298 (2006).
41. Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med. 197, 1073-1081 (2003).
42. Ellmerich S, Mycko M, Takacs K et al. High incidence of spontaneous disease in an HLA-DR15 and TCR transgenic multiple sclerosis model. J. Immunol. 174, 1938-1946 (2005).
43. Waldner H, Whitters MJ, Sobel RA, Collins M, Kuchroo VK. Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor. Proc. Natl. Acad. Sci. 97, 3412-3417 (2000).
44. Lafaille JJ, Nagashima K, Katsuki M, Tonegawa S. High incidence of spontaneous autoimmune encephalomyelitis in immunodeficient anti-myelin basic protein T cell receptor transgenic mice. Cell 78, 399-408 (1994).
45. Olivares-Villagomez D, Wang Y, Lafaille JJ. Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J. Exp. Med. 188, 1883-1894 (1998).
46. Bettelli E, Baeten D, Jager A, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J. Clin. Invest. 116, 2393-2402 (2006).
47. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J. Clin. Invest. 116, 2385-2392 (2006).
48. Ransohoff RM. A mighty mouse: building a better model of multiple sclerosis. J. Clin. Invest. 116, 2313-2316 (2006).
49. Waldor MK, Sriram S, Hardy R et al. Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science 227, 415-417 (1985).
50. Sedgwick JD, Mason DW. The mechanism of inhibition of experimental allergic encephalomyelitis in the rat by monoclonal antibody against CD4. J. Neuroimmunol. 13, 217-232 (1986).
51. McDevitt HO, Perry R, Steinman LA. Monoclonal anti-Ia antibody therapy in animal models of autoimmune disease. Ciba Found. Symp. 129, 184-193 (1987).
52. Jameson BA, McDonnell JM, Marini JC, Korngold R. A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis. Nature 368, 744-746 (1994).
53. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233-240 (2005).
54. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179-189 (2006).
55. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 11, 335-339 (2005).
56. Kawakami N, Lassmann S, Li Z et al. The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. J. Exp. Med. 199, 185-197 (2004).
57. Kawakami N, Nagerl UV, Odoardi F, Bonhoeffer T, Wekerle H, Flugel A. Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion. J. Exp. Med. 201, 1805-1814 (2005).
58. Krakowski ML, Owens T. Naive T lymphocytes traffic to inflamed central nervous system, but require antigen recognition for activation. Eur. J. Immunol. 30, 1002-1009 (2000).
59. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 28, 254-260 (1991).
60. Zeine R, Owens T. Direct demonstration of the infiltration of murine central nervous system by Pgp-1/CD44high CD45RB(low) CD4+ T cells that induce experimental allergic encephalomyelitis. J. Neuroimmunol. 40, 57-69 (1992).
61. Tompkins SM, Padilla J, Dal Canto MC, Ting JP, Van Kaer L, Miller SD. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. J. Immunol. 168, 4173-4183 (2002).
62. Hickey WF, Kimura H. Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 239, 290-292 (1988).
63. Ford AL, Goodsall AL, Hickey WF, Sedgwick JD. Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared. J. Immunol. 154, 4309-4321 (1995).
64. Katz-Levy Y, Neville KL, Girvin AM et al. Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice. J. Clin. Invest. 104, 599-610 (1999).
65. Juedes AE, Ruddle NH. Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. J. Immunol. 166, 5168-5175 (2001).
66. Aloisi F, Ria F, Adorini L. Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol. Today 21, 141-147 (2000).
67. McMahon EJ, Bailey SL, Miller SD. CNS dendritic cells: critical participants in CNS inflammation. Neurochem. Intl. 49, 195-203 (2006).
68. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17, 51-88 (1999).
69. Sercarz EE, Lehmann PV, Ametani A, Benichou G, Miller A, Moudgil K. Dominance and crypticity of T cell antigenic determinants. Annu. Rev. Immunol. 11, 729-766 (1993).
70. Miller SD, Vanderlugt CL, Begolka WS et al. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat. Med. 3, 1133-1136 (1997).
71. Katz-Levy Y, Neville KL, Girvin AM et al. Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice. J. Clin. Invest. 104, 599-610 (1999).
72. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182, 75-85 (1995).
73. Vanderlugt CL, Eagar TN, Neville KL, Nikcevich KM, Bluestone JA, Miller SD. Pathologic role and temporal appearance of newly emerging autoepitopes in relapsing experimental autoimmune encephalomyelitis. J. Immunol. 164, 670-678 (2000).
74. Pircher H, Moskophidis D, Rohrer U, Burki K, Hengartner H, Zinkernagel RM. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 346, 629-633 (1990).
75. Phillips RE, Rowland-Jones S, Nixon DF et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354, 453-459 (1991).
76. Lehmann PV, Forsthuber T, Miller A, Sercarz EE. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358, 155-157 (1992).
77. Yu M, Johnson JM, Tuohy VK. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: A basis for peptide-specific therapy after onset of clinical disease. J. Exp. Med. 183, 1777-1788 (1996).
78. Katz-Levy Y, Neville KL, Padilla J et al. Temporal development of autoreactive Th1 responses and endogenous antigen presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice. J. Immunol. 165, 5304-5314 (2000).
79. Neville KL, Padilla J, Miller SD. Myelin-specific tolerance attenuates the progression of a virus-induced demyelinating disease: Implications for the treatment of MS. J. Neuroimmunol. 123, 18-29 (2002).
80. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2, 85-95 (2002).
81. McFarland HI, Lobito AA, Johnson MM et al. Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis. J. Immunol. 162, 2384-2390 (1999).
82. Robinson WH, Fontoura P, Lee BJ et al. Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat. Biotechnol. 21(9), 1033-1039 (2003).
83. Bischof F, Bins A, Durr M, Zevering Y, Melms A, Kruisbeek AM. A structurally available encephalitogenic epitope of myelin oligodendrocyte glycoprotein specifically induces a diversified pathogenic autoimmune response. J. Immunol. 173, 600-606 (2004).
84. Kanter JL, Narayana S, Ho PP et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med. 12, 138-143 (2006).
85. Hjelmstrom P, Juedes AE, Fjell J, Ruddle NH. B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. J. Immunol. 161, 4480-4483 (1998).
86. Anderton SM, Viner NJ, Matharu P, Lowrey PA, Wraith DC. Influence of a dominant cryptic epitope on autoimmune T cell tolerance. Nat. Immunol. 3, 175-181 (2002).
87. Tuohy VK, Yu M, Yin L, Kawczak JA, Kinkel RP. Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med. 189, 1033-1042 (1999).
88. Steinman L. Absence of "original antigenic sin" in autoimmunity provides an unforeseen platform for immune therapy. J. Exp. Med. 189, 1021-1024 (1999).
89. Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 148, 11-23 (2004).
90. Lee SC, Raine CS. Multiple sclerosis: oligodendrocytes in active lesions do not express class II major histocompatibility complex molecules. J. Neuroimmunol. 25, 261-266 (1989).
91. Plumb J, Armstrong MA, Duddy M, Mirakhur M, McQuaid S. CD83-positive dendritic cells are present in occasional perivascular cuffs in multiple sclerosis lesions. Mult. Scler. 9, 142-147 (2003).
92. Huang YM, Xiao BG, Ozenci V et al. Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. J. Neuroimmunol. 99, 82-90 (1999).
93. Behi ME, Dubucquoi S, Lefranc D et al. New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Lett. 96, 11-26 (2005).
94. Sanna A, Fois ML, Arru G et al. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin. Exp. Immunol. 143, 357-362 (2006).
95. Flugel A, Berkowicz T, Ritter T et al. Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity. 14, 547-560 (2001).
96. Schmied M, Breitschopf H, Gold R et al. Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis. Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am. J. Pathol. 143, 446-452 (1993).
97. Tabi Z, McCombe PA, Pender MP. Apoptotic elimination of V beta 8.2+ cells from the central nervous system during recovery from experimental autoimmune encephalomyelitis induced by the passive transfer of V beta 8.2+ encephalitogenic T cells. Eur. J. Immunol. 24, 2609-2617 (1994).
98. Suvannavejh GC, Dal Canto MC, Matis LA, Miller SD. Fas-mediated apoptosis in clinical remissions of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 105, 223-231 (2000).
99. Bischof F, Hofmann M, Schumacher TN et al. Analysis of autoreactive CD4 T cells in experimental autoimmune encephalomyelitis after primary and secondary challenge using MHC class II tetramers. J. Immunol. 172, 2878-2884 (2004).
100. Targoni OS, Baus J, Hofstetter HH et al. Frequencies of neuroantigen-specific T cells in the central nervous system versus the immune periphery during the courseof experimental allergic encephalomyelitis. J. Immunol. 166, 4757-4764 (2001).
101. Conant SB, Swanborg RH. Autoreactive T cells persist in rats protected against experimental autoimmune encephalomyelitis and can be activated through stimulation of innate immunity. J. Immunol. 172, 5322-5328 (2004).
102. Asano M, Toda M, Sakaguchi N, Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184, 387-396 (1996).
103. + T cells with regulatory properties from human blood. J. Exp. Med. 193, 1303-1310 (2001).
104. + T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193, 1285-1294 (2001).
105. Shevach EM. CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2, 389-400 (2002).
106. - T cells. J. Clin. Invest. 112, 1437-1443 (2003).
107. von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity. Nat. Rev. Immunol. 3, 223-232 (2003).
108. + regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 101, 15434-15439 (2004).
109. Reddy J, Waldner H, Zhang X et al. Cutting edge: CD4+CD25+ regulatory T cells contribute to gender differences in susceptibility to experimental autoimmune encephalomyelitis. J. Immunol. 175, 5591-5595 (2005).
110. Kohm AP, Carpentier PA, Anger HA, Miller SD. Cutting Edge CD4(+)CD25(+) regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 169, 4712-4716 (2002).
111. McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. J. Immunol. 175, 3025-3032 (2005).
112. + Treg cells. J. Immunol. 176, 3301-3305 (2006).
113. Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nat. Rev. Immunol. 5, 343-349 (2005).
114. Mekala DJ, Geiger TL. Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes. Blood 105, 2090-2092 (2005).
115. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
116. Khoury SJ, Hancock WW, Weiner HL. Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J. Exp. Med. 176, 1355-1364 (1992).
117. Powrie F, Menon S, Coffman RL. Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo. Eur. J. Immunol. 23, 3043-3049 (1993).
118. Begolka WS, Vanderlugt CL, Rahbe SM, Miller SD. Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J. Immunol. 161, 4437-4446 (1998).
119. Cua DJ, Coffman RL, Stohlman SA. Exposure to T helper 2 cytokines in vivo before encounter with antigen selects for T helper subsets via alterations in antigen-presenting cell function. J. Immunol. 157, 2830-2836 (1996).
120. Lafaille JJ, Van de Keere F, Hsu AL et al. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 186, 307-312 (1997).
121. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 343, 938-952 (2000).
122. Kesselring J, Beer S. Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol. 4, 643-652 (2005).
123. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43, 655-661 (1993).
124. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43, 662-667 (1993).
125. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45, 1277-1285 (1995).
126. Ebers GC, Hommes O, Hughes RAC et al. Randomised double-blind placebo-controlled study of interferon beta-Ia in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352, 1498-1504 (1998).
127. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis). Ann. Neurol. 46, 197-206 (1999).
128. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56, 1628-1636 (2001).
129. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer I Multiple Sclerosis Study Group. Neurology 45, 1268-1276 (1995).
130. Johnson KP, Brooks BR, Cohen JA et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 50, 701-708 (1998).
131. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 352, 1491-1497 (1998).
132. Panitch H, Miller A, Paty D, Weinshenker B. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 63, 1788-1795 (2004).
133. Kappos L, Weinshenker B, Pozzilli C et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 63, 1779-1787 (2004).
134. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Clinical results. Neurology 56, 1496-1504 (2001).
135. Li DK, Zhao GJ, Paty DW. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. MRI results. Neurology 56, 1505-1513 (2001).
136. Cohen JA, Cutter GR, Fischer JS et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology 59, 679-687 (2002).
137. Tuohy VK, Yu M, Yin L, Mathisen PM, Johnson JM, Kawczak JA. Modulation of the IL-10/IL-12 cytokine circuit by interferon-β inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis. J. Neuroimmunol. 111, 55-63 (2000).
138. Goodin DS, Frohman EM, Garmany GP et al. Disease modifying therapies in multiple sclerosis - Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58, 169-178 (2002).
139. Lublin F. History of modern multiple sclerosis therapy. J. Neurol. 252(Suppl. 3), iii3-iii9 (2005).
140. Frohman EM, Racke MK, Raine CS. Multiple sclerosis - the plaque and its pathogenesis. N. Engl. J. Med. 354, 942-955 (2006).
141. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899-910 (2006).
142. Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 354, 911-923 (2006).
143. Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354, 924-933 (2006).
144. Ropper AH. Selective treatment of multiple sclerosis. N. Engl. J. Med. 354, 965-967 (2006).
145. Hohlfeld R, and Wekerle, H. Drug insight: Using monoclonal antibodies to treat multiple sclerosis. Nat. Clin. Practice Neurol. 1, 34-44 (2005).
146. Neville KL, Dal Canto MC, Bluestone JA, Miller SD. CD28 costimulatory blockade exacerbates disease severity and accelerates epitope spreading in a virus-induced autoimmune disease. J. Virol. 74, 8349-8357 (2000).
147. Miller SD, Vanderlugt CL, Lenschow DJ et al. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 3, 739-745 (1995).
148. Howard LM, Miga A, Vanderlugt CL et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. 103, 281-290 (1999).
149. Karandikar NJ, Eagar TN, Vanderlugt CL, Bluestone JA, Miller SD. CTLA-4 downregulates epitope spreading and mediates remission in autoimmune disease. J. Neuroimmunol. 109, 173-180 (2000).
150. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat. Med. 6, 114 (2000).
151. Couzin J. Drug discovery. Magnificent obsession. Science 307, 1712-1715 (2005).
152. Beyersdorf N, Gaupp S, Balbach K et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J. Exp. Med. 202, 445-455 (2005).
153. Hopkin M. Can super-antibody drugs be tamed? Nature 440, 855-856 (2006).
154. Killestein J, Polman CH. Current trials in multiple sclerosis: established evidence and future hopes. Curr. Opin. Neurol. 18, 253-260 (2005).
155. Kieseier BC, Hemmer B, Hartung HP. Multiple sclerosis - novel insights and new therapeutic strategies. Curr. Opin. Neurol. 18, 211-220 (2005).
156. Fontoura P, Steinman L, Miller A. Emerging therapeutic targets in multiple sclerosis. Curr. Opin. Neurol. 19, 260-266 (2006).
157. Selzer ME. Promotion of axonal regeneration in the injured CNS. Lancet Neurol. 2, 157-166 (2003).
158. Killestein J, Kalkers NF, Polman CH. Glutamate inhibition in MS: the neuroprotective properties of riluzole. J. Neurol. Sci. 233, 113-115 (2005).
159. Kohm AP, Turley DM, Miller SD. Targeting the TCR. T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease. Int. Rev. Immunol. 24, 361-392 (2005).
160. Sospedra M, Martin R. Antigen-specific therapies in multiple sclerosis. Int. Rev. Immunol. 24, 393-413 (2005).
161. Elliott EA, McFarland HI, Nye SH et al. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J. Clin. Invest. 98, 1602-1612 (1996).
162. McFarland HI, Lobito AA, Johnson MM et al. Effective antigen-specific immunotherapy in the marmoset model of multiple sclerosis. J. Immunol. 166, 2116-2121 (2001).
163. Zhong MC, Kerlero de RN, Ben-Nun A. Multiantigen/multiepitope-directed immune-specific suppression of "complex autoimmune encephalomyelitis" by a novel protein product of a synthetic gene. J. Clin. Invest. 110, 81-90 (2002).
164. Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 4, 567-575 (2005).
165. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc. Natl. Acad. Sci. USA 102, 6449-6454 (2005).
166. Stern JN, Illes Z, Reddy J et al. Amelioration of proteolipid protein 139-151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms. Proc. Natl. Acad. Sci. USA 101, 11743-11748 (2004).
167. Shukaliak Quandt J, Borras E, Prat E et al. Peptidic complex mixtures as therapeutic agents in CNS autoimmunity. Mol. Immunol. 40, 1075-1087 (2004).
168. Garren H, Antel A, Bar-Or A et al. Phase I/II trial of a MBP encoding DNA plasmid (BHT 3009) alone or in combination with atorvastatin for treatment of multiple sclerosis. 16th Meeting of the European Neurological Society 27.05.2006 to 31.05.2006; Lausanne, Switzerland (2006).
169. McCarron RM, Fallis RJ, McFarlin DE. Alterations in T cell antigen specificity and class II restriction during the course of chronic relapsing experimental allergic encephalomyelitis. J. Neuroimmunol. 29, 73-79 (1990).
170. Perry LL, Barzaga-Gilbert E, Trotter JL. T cell sensitization to proteolipid protein in myelin basic protein-induced experimental allergic encephalomyelitis. J. Neuroimmunol. 33, 7-16 (1991).
171. Jansson L, Diener P, Engstrom A, Olsson T, Holmdahl R. Spreading of the immune response to different myelin basic protein peptides in chronic experimental autoimmune encephalomyelitis in B10.RIII mice. Eur. J. Immunol. 25, 2195-2200 (1995).
172. Zhang GX, Yu S, Gran B et al. T cell and antibody responses in remitting-relapsing experimental autoimmune encephalomyelitis in (C57BL/ 6 × SJL) F1 mice. J. Neuroimmunol. 148, 1-10 (2004).
173. Klehmet J, Shive C, Guardia-Wolff R et al. T cell epitope spreading to myelin oligodendrocyte glycoprotein in HLA-DR4 transgenic mice during experimental autoimmune encephalomyelitis. Clin. Immunol. 111, 53-60 (2004).
174. Ellmerich S, Takacs K, Mycko M et al. Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis. Eur. J. Immunol. 34, 1839-1848 (2004).
175. Borrow P, Welsh CJ, Tonks P, Dean D, Blakemore WF, Nash AA. Investigation of the role of delayed-type-hypersensitivity responses to myelin in the pathogenesis of Theiler's virus-induced demyelinating disease. Immunology 93, 478-484 (1998).
176. Uccelli A, Ristori G, Giunti D et al. Dynamics of the reactivity to MBP in multiple sclerosis. J. Neurovirol. 6(Suppl. 2), S52-S56 (2000).
177. Ristori G, Giubilei F, Giunti D et al. Myelin basic protein intramolecular spreading without disease progression in a patient with multiple sclerosis. J. Neuroimmunol. 110, 240-243 (2000).
178. Davies S, Nicholson T, Laura M, Giovannoni G, Altmann DM. Spread of T lymphocyte immune responses to myelin epitopes with duration of multiple sclerosis. J. Neuropathol. Exp. Neurol. 64, 371-377 (2005).
179. Muraro PA, Wandinger KP, Bielekova B et al. Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain 126, 20-31 (2003).
180. Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 123, 508-518 (2000).
181. Tuohy VK, Yu M, Weinstock-Guttman B, Kinkel RP. Diversity and plasticity of self recognition during the development of multiple sclerosis. J. Clin. Invest. 99, 1682-1690 (1997).
182. Tuohy VK, Yu M, Yin L et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Rev. 164, 93-100 (1998).
183. Bielekova B, Catalfamo M, Reichert-Scrivner S et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA 103, 5941-5946 (2006).
184. Matloubian M, Lo CG, Cinamon G et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427, 355-360 (2004).
185. Klotz L, Schmidt M, Giese T et al. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor γ levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J. Immunol. 175, 4948-4955 (2005).
186. Diab A, Deng C, Smith JD et al. Peroxisome proliferator-activated receptor-γ agonist 15-deoxy-Delta(12,14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 168, 2508-2515 (2002).
187. Youssef S, Stuve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420, 78-84 (2002).